Search Result

Results for "

higher affinity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Adenosine Receptor (1) Adrenergic Receptor (4) Antibiotic (1) Apoptosis (4) Autophagy (2) Bacterial (1) Bcl-2 Family (1) Biochemical Assay Reagents (1) Calcium Channel (1) Cholinesterase (ChE) (1) Cytochrome P450 (3) Dopamine Receptor (1) Drug Metabolite (4) Elastase (1) ERK (1) Estrogen Receptor/ERR (5) Histamine Receptor (3) HSP (1) Influenza Virus (1) Isotope-Labeled Compounds (3) Leukotriene Receptor (1) Melanocortin Receptor (2) mGluR (1) Mitophagy (1) nAChR (3) Neuropeptide Y Receptor (2) Parasite (3) Phosphatase (3) PPAR (1) Progesterone Receptor (1) RAR/RXR (2) Reactive Oxygen Species (1) Serotonin Transporter (5) Thyroid Hormone Receptor (1) Trk Receptor (1) TRP Channel (1) YAP (2)
By Research Areas:	Cancer (18) Cardiovascular Disease (3) Endocrinology (6) Infection (2) Inflammation/Immunology (9) Metabolic Disease (7) Neurological Disease (22)

By Targets:

5-HT Receptor (3)

Adenosine Receptor (1)

Adrenergic Receptor (4)

Antibiotic (1)

Apoptosis (4)

Autophagy (2)

Bacterial (1)

Bcl-2 Family (1)

Biochemical Assay Reagents (1)

Calcium Channel (1)

Cholinesterase (ChE) (1)

Cytochrome P450 (3)

Dopamine Receptor (1)

Drug Metabolite (4)

Elastase (1)

ERK (1)

Estrogen Receptor/ERR (5)

Histamine Receptor (3)

HSP (1)

Influenza Virus (1)

Isotope-Labeled Compounds (3)

Leukotriene Receptor (1)

Melanocortin Receptor (2)

mGluR (1)

Mitophagy (1)

nAChR (3)

Neuropeptide Y Receptor (2)

Parasite (3)

Phosphatase (3)

PPAR (1)

Progesterone Receptor (1)

RAR/RXR (2)

Reactive Oxygen Species (1)

Serotonin Transporter (5)

Thyroid Hormone Receptor (1)

Trk Receptor (1)

TRP Channel (1)

YAP (2)

By Research Areas:

Cancer (18)

Cardiovascular Disease (3)

Endocrinology (6)

Infection (2)

Inflammation/Immunology (9)

Metabolic Disease (7)

Neurological Disease (22)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10684

Pridopidine ACR16; ASP2314; FR310826	Dopamine Receptor	Neurological Disease
Pridopidine, a dopamine (DA) stabilizer, acts as a low affinity dopamine D2 receptor (D2R) antagonist. Pridopidine exerts high affinity towards sigma 1 receptor (S1R) with K_i between 70 and 80 nM, which is ~100× higher than its affinity toward D2R.

HY-P3205

Lysyl endopeptidase, Achromobacter sp Lys-C	Others	Others
Lysyl endopeptidase, Achromobacter sp (Lys-C) catalyzes carboxyl oxygen exchange reaction. Lysyl endopeptidase has higher substrate binding affinities and higher catalytic rates at the acidic pHs than at the alkaline pHs .

HY-119518

BMS641 BMS-209641	RAR/RXR	Cancer
BMS641 (BMS-209641) is a selective RARβ agonist. BMS641 has a higher affinity for RARβ (K_d, 2.5 nM) that is 100 times higher than that for RARα (K_d, 225 nM) or RARγ (K_d, 223 nM) .

HY-121166

Levobetaxolol (S)-Betaxolol	Adrenergic Receptor	Others
Levobetaxolol is a potent and high affinity β-adrenergic antagonist with IC₅₀ values of 33.2, 2970, 709 nM for guinea pig atrial β1, tracheal β2 and rat colonic β3 receptors, respectively. Levobetaxolol reduces IOP (intraocular pressure). Levobetaxolol exhibits a micromolar affinity for L-type Ca21-channels. Levobetaxolol decreases the effects of ischaemia/reperfusion injury in rats. Levobetaxolol has the potential for the research of glaucoma .

HY-101686

LM-1484

Leukotriene Receptor Inflammation/Immunology

LM-1484 is an antagonist of CysLT1 receptor and displays a higher affinity for ³H-LTC4 sites.

LM-1484	Leukotriene Receptor	Inflammation/Immunology
LM-1484 is an antagonist of CysLT1 receptor and displays a higher affinity for ³H-LTC4 sites.

HY-P1135

M1145	Neuropeptide Y Receptor	Neurological Disease
M1145, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a K_i of 6.55 nM. M1145 shows more than 90-fold higher affinity for GAL2 over GAL1 (K_i=587 nM) and a 76-fold higher affinity over GalR3 (K_i=497 nM). M1145 has an additive effect on the signal transduction of galanin .

HY-P1135A

M1145 TFA	Neuropeptide Y Receptor	Neurological Disease
M1145 TFA, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a K_i of 6.55 nM. M1145 TFA shows more than 90-fold higher affinity for GAL2 over GAL1 (K_i=587 nM) and a 76-fold higher affinity over GalR3 (K_i=497 nM). M1145 TFA has an additive effect on the signal transduction of galanin .

HY-100202

TPEN 10+ Cited Publications TPEDA	Reactive Oxygen Species Apoptosis Autophagy	Cancer
TPEN (TPEDA) is a specific cell-permeable heavy metal chelator. TPEN has a higher affinity for Zn ²⁺, but a lower affinity for Mg ²⁺ and Ca ²⁺. TPEN induces DNA damage and increases intracellular ROS production. TPEN also inhibits cell proliferation and induces apoptosis .

HY-156394

Laxiflorin B-4

ERK Cancer

Laxiflorin B-4 is modificative compound of Laxiflorin B (HY-156393), exhibited higher affinity for ERK1/2 and stronger tumor suppression .

Laxiflorin B-4	ERK	Cancer
Laxiflorin B-4 is modificative compound of Laxiflorin B (HY-156393), exhibited higher affinity for ERK1/2 and stronger tumor suppression .

HY-15606

Tanaproget 1 Publications Verification NSP-989	Progesterone Receptor	Endocrinology
Tanaproget (NSP-989) is a novel nonsteroidal progesterone receptor agonist which can bind to the PR from various species with a higher relative affinity than reference steroidal progestins.

HY-18719B

Endoxifen hydrochloride	Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite	Cancer
Endoxifen hydrochloride is a key active metabolite of Tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen hydrochloride has the potential for breast cancer study .

HY-18719E

Endoxifen	Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite	Cancer
Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study .

HY-124414

4'-Hydroxytamoxifen	Estrogen Receptor/ERR Drug Metabolite	Cancer
4'-Hydroxytamoxifen is a metabolite of Tamoxifen. 4'-Hydroxytamoxifen shows higher affinity for the ER than Tamoxifen. 4'-Hydroxytamoxifen induces a non-apoptotic cytotoxic effect in human endometrial adenocarcinoma cells .

HY-P3654

α-Conotoxin S IA	nAChR	Neurological Disease
α-Conotoxin SIA is a selective nicotinic acetylcholine receptor (nAChR) antagonist with high affinity for the muscle nAChR. α-Conotoxin SIA preferentially targets the α/δ interface of the muscle nAChR in mouse muscle. In contrast, for Torpedo nAChR, α-Conotoxin SIA has a much higher affinity for the α/γ than for the α/δ interface .

HY-15553B

Mibefradil dihydrochloride hydrate Ro 40-5967 dihydrochloride hydrate	Calcium Channel	Cardiovascular Disease
Mibefradil dihydrochloride hydrate (Ro 40-5967 dihydrochloride hydrate) is a effectively long-acting calcium channel antagonist, used as an antihypertensive agent. Mibefradil dihydrochloride hydrate acts via a higher affinity block for low-voltage-activated (T) than for high-voltage-activated (L) calcium channels .

HY-147908

Adenosine receptor inhibitor 2	Adenosine Receptor	Inflammation/Immunology
Adenosine receptor inhibitor 2 (compound 14b) is a potent AR (adenosine receptor) inhibitor. Adenosine receptor inhibitor 2 shows dual affinity toward A₁/A_2A ARs with higher affinity for the A₁- than the A_2AAR. Adenosine receptor inhibitor 2 has K_i values of 52.2 nM for the A₁AR and 167 nM for the A_2AAR .

HY-18719ES

Endoxifen-d5	Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite	Cancer
Endoxifen-d₅ is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study[1][2].

HY-100943

Cinanserin hydrochloride 1 Publications Verification SQ 10643	5-HT Receptor Influenza Virus	Infection Inflammation/Immunology
Cinanserin hydrochloride (SQ 10643) is a potent, selective and highly affinity 5-HT₂ receptor antagonist with a K_i of 41 nM. Cinanserin hydrochloride has a much higher binding affinity for the 5-HT₂ than for the 5-HT₁ receptor (K_i of 3500 nM). Cinanserin is also an inhibitor of 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro .

HY-122140

ACG548B	Cholinesterase (ChE)	Neurological Disease
ACG548B (compound 24) is a potent inhibitor of acetyl- and butyrylcholinesterase (AChE and BChE) with IC₅₀s of 1.78 and 0.496 μM, respectively. ACG548B has higher AChE affinity and selectivity over BChE and ChoK (choline kinase) .

HY-103138A

(Rac)-WAY-161503	5-HT Receptor	Neurological Disease Metabolic Disease
(Rac)-WAY-161503 is a potent, selective, highly affinity 5-HT_2C receptor agonist with a K_i of 4 nM and an EC₅₀ of 12 nM. (Rac)-WAY-161503 displays higher affinity for 5-HT_2C than 5-HT_2A and 5-HT_2B receptors. (Rac)-WAY-161503 has anti-obesity and antidepressant effects .

HY-103138

(Rac)-WAY-161503 hydrochloride	5-HT Receptor	Neurological Disease Metabolic Disease
(Rac)-WAY-161503 hydrochloride is a potent, selective, high affinity 5-HT_2C receptor agonist with a K_i of 4 nM and an EC₅₀ of 12 nM. (Rac)-WAY-161503 hydrochloride displays higher affinity for 5-HT_2C than 5-HT_2A and 5-HT_2B receptors. (Rac)-WAY-161503 hydrochloride has anti-obesity and antidepressant effects .

HY-100689

Propyl pyrazole triol 10+ Cited Publications PPT
Propyl pyrazole triol (PPT) is a selective estrogen receptor alpha (ERα) agonist. The relative binding affinity of Propyl pyrazole triol for ERα (ERα: 49%) around 410 times higher compared with estrogen receptor beta (ERβ: 0.12%) .

HY-103451

(R,R)-THC	Estrogen Receptor/ERR	Metabolic Disease
(R,R)-THC is an ERα agonist and an ERβ antagonist, with K_is of 9.0 nM and 3.6 nM for ERα and ERβ, respectively. (R,R)-THC has higher relative binding affinity for ERβ than ERα with the values of 25 and 3.6 .

HY-10473

Eprotirome KB2115	Thyroid Hormone Receptor	Metabolic Disease Endocrinology
Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research .

HY-P2244

YAP-TEAD-IN-1	YAP	Cancer
YAP-TEAD-IN-1 is a potent and competitive inhibitor of YAP–TEAD interaction (IC₅₀=25 nM). YAP-TEAD-IN-1 is a 17mer peptide and shows a higher the binding affinity to TEAD1 (K_d=15 nM) than YAP (50-171) (K_d=40 nM) .

HY-14258

Escitalopram 3 Publications Verification (S)-Citalopram; (S)-(+)-Citalopram	Serotonin Transporter	Neurological Disease
Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression .

HY-U00165

Midaglizole hydrochloride (±)-DG5128; DG5128	Adrenergic Receptor	Metabolic Disease Endocrinology
Midaglizole hydrochloride (DG5128) is a preferential α2-adrenoceptor antagonist. Midaglizole hydrochloride (DG5128) exhibits 7.4 times higher affinity (pK_i=6.28) toward α2-adrenoceptor than α1-adrenoceptor.

HY-B0814

Levocetirizine (R)-Cetirizine
Levocetirizine ((R)-Cetirizine) is a third-generation peripheral H1-receptor antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria .

HY-W010841

Levocetirizine dihydrochloride (R)-Cetirizine dihydrochloride	Histamine Receptor	Inflammation/Immunology Endocrinology
Levocetirizine dihydrochloride ((R)-Cetirizine dihydrochloride) is a third-generation peripheral H1-receptor antagonist. Levocetirizine dihydrochloride is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine dihydrochloride has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria .

HY-P2244A

YAP-TEAD-IN-1 TFA 2 Publications Verification	YAP	Cancer
YAP-TEAD-IN-1 TFA is a potent and competitive peptide inhibitor of YAP-TEAD interaction (IC₅₀=25 nM). YAP-TEAD-IN-1 TFA is a 17mer peptide and shows a higher the binding affinity to TEAD1 (K_d=15 nM) than YAP (50-171) (K_d= 40 nM) .

HY-P2468

BAD (103-127) (human) BADBH3 103-127 (human); BADBH3 (human)	Bcl-2 Family	Cancer
BAD (103-127) (human), the 25-mer Bad peptide, is derived from the BH3 domain of BAD, can antagonize the function of Bcl-xL. BAD (103-127) (human) is reported to have almost 800-fold higher affinity for Bcl-XL than the 16-mer peptide .

HY-157287

(S)-Phe-A110/B319	Others	Inflammation/Immunology
(S)-Phe-A110/B319 is a selective binde that has 20-fold higher affinity towards the H1047R mutant of p110α in the p110α/p85α PI3K complex .

HY-14258A

Escitalopram oxalate 3 Publications Verification (S)-Citalopram oxalate; (S)-(+)-Citalopram oxalate	Serotonin Transporter	Neurological Disease
Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .

HY-P1213A

JKC363 TFA	Melanocortin Receptor	Neurological Disease
JKC363 TFA, a selective melanocortin MC4 receptor antagonist, has a 90-fold higher affinity at the MC4 receptor (IC₅₀=0.5 nM) than at the MC3 receptor (44.9 nM). JKC363 TFA blocks the stimulatory effect of α-MSH on TRH release. Anti-hyperalgesic effect .

HY-P1213

JKC363	Melanocortin Receptor	Neurological Disease
JKC363, a selective melanocortin MC4 receptor antagonist, has a 90-fold higher affinity at the MC4 receptor (IC₅₀=0.5 nM) than at the MC3 receptor (44.9 nM). JKC-363 blocks the stimulatory effect of α-MSH on TRH release. Anti-hyperalgesic effect .

HY-103197

2-Methoxyidazoxan monohydrochloride RX821002 hydrochloride	Adrenergic Receptor	Neurological Disease
2-Methoxyidazoxan monohydrochloride (RX821002 hydrochloride) is a highly selective alpha 2-adrenoceptor antagonist with little or no imidazoline antagonist effect. RX 821002 has markedly higher affinity for (guinea-pig) alpha 2D-adrenoceptors (pK_d 9.7) than for (rabbit) alpha 2A-adrenoceptors (pK_d 8.2) .

HY-103445

SSR69071	Elastase	Cardiovascular Disease
SSR69071 is a potent, orally active and selective inhibitor of neutrophil elastase. SSR69071 reduces myocardial infarct size following ischemia-reperfusion injury . SSR69071 displays a higher affinity for human elastase (K_i=0.0168 nM) than for rat (K_i=3 nM), mouse (K_i=1.8 nM), and rabbit (K_i= 58 nM) elastases .

HY-161008

Heroin-CH2-acid	Others	Cancer
Heroin-CH2-acid a hapten that can be coupled with bovine serum albumin (BSA). Heroin-CH2-acid vaccine elicited both greater quantities as well as equivalent or higher affinity antibodies towards heroin and 6-AM. Heroin-CH2-acid plays an important role in opioid use disorder .

HY-117239

SB-206606	Adrenergic Receptor	Cardiovascular Disease
SB-206606, a stereoisomer of BRL 37344, is a potentially specific, beta 3-adrenergic receptor (β₃-AR) ligand. The affinity of [3H]SB 206606 is 76 times higher for the β₃-AR than for the beta 1/beta 2-adrenergic receptors .

HY-116247

ST247	PPAR	Metabolic Disease Inflammation/Immunology
ST247 a potent PPARβ/δ inverse agonist. ST247 has a higher affinity to PPARβ/δ. ST247 modulates expression of the activation marker CCL2 in the opposite direction. ST247 efficiently induces the interaction with corepressors. ST247 inhibits the agonist-induced transcriptional activity of PPARβ/δ .

HY-B0814S

Levocetirizine-d4 dihydrochloride (R)-Cetirizine-d₄(dihydrochloride)	Isotope-Labeled Compounds Histamine Receptor	Inflammation/Immunology Endocrinology
Levocetirizine-d₄ (dihydrochloride) is the deuterium labeled Levocetirizine. Levocetirizine ((R)-Cetirizine) is a third-generation peripheral H1-receptor antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria[1].

HY-137231B

(S)-UFR2709 hydrochloride	nAChR	Neurological Disease
(S)-UFR2709 (hydrochloride) is a competitive nAChR antagonist and displays higher affinity for α₄β₂ nAChRs than for α₇ nAChRs. (S)-UFR2709 (hydrochloride) decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats. (S)-UFR2709 (hydrochloride) acts as an anxiolytic agent and can be used for the study of nicotine addiction .

HY-137231A

(S)-UFR2709	nAChR	Neurological Disease
(S)-UFR2709 is a competitive nAChR antagonist and displays higher affinity for α₄β₂ nAChRs than for α₇ nAChRs. (S)-UFR2709 decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats. (S)-UFR2709 acts as an anxiolytic agent and can be used for the study of nicotine addiction .

HY-W010841R

Levocetirizine dihydrochloride (Standard) (R)-Cetirizine dihydrochloride (Standard)	Histamine Receptor	Inflammation/Immunology Endocrinology
Levocetirizine (dihydrochloride) (Standard) is the analytical standard of Levocetirizine (dihydrochloride). This product is intended for research and analytical applications. Levocetirizine dihydrochloride ((R)-Cetirizine dihydrochloride) is a third-generation peripheral H1-receptor antagonist. Levocetirizine dihydrochloride is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine dihydrochloride has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria .

HY-10211

Tanespimycin Maximum Cited Publications 35 Publications Verification 17-AAG; NSC 330507; CP 127374	HSP Autophagy Mitophagy Bacterial Apoptosis Antibiotic	Infection Cancer
Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC₅₀ of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .

HY-14258AS

Escitalopram-d6 oxalate	Serotonin Transporter	Neurological Disease
Escitalopram-d₆ (oxalate) is the deuterium labeled Escitalopram oxalate. Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression[1][2].

HY-14258AS1

Escitalopram-d4 oxalate (S)-Citalopram-d₄ oxalate; (S)-(+)-Citalopram-d₄ oxalate	Isotope-Labeled Compounds Serotonin Transporter	Neurological Disease
Escitalopram-d₄ (oxalate) is deuterium labeled Escitalopram (oxalate). Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression[1][2].

HY-107436

LE135 1 Publications Verification	RAR/RXR TRP Channel	Neurological Disease Cancer
LE135 is a potent RAR antagonist that binds selectively to RARα (K_i of 1.4 μM) and RARβ (K_i of 220 nM), and has a higher affinity to RARβ. LE135 is highly selective over RARγ, RXRα, RXRβ and RXRγ. LE135 is also a potent TRPV1 and TRPA1 receptors activator with EC₅₀s of 2.5 μM and 20 μM, respectively .

HY-14258AR

Escitalopram oxalate (Standard) (S)-Citalopram oxalate (Standard); (S)-(+)-Citalopram oxalate (Standard)	Serotonin Transporter	Neurological Disease Cancer
Escitalopram (oxalate) (Standard) is the analytical standard of Escitalopram (oxalate). This product is intended for research and analytical applications. Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .

HY-B0814S1

Levocetirizine-d4 (R)-Cetirizine-d₄	Isotope-Labeled Compounds	Inflammation/Immunology
Levocetirizine-d₄ ((R)-Cetirizine-d₄) is the deuterium-labeled Levocetirizine (HY-B0814) . Levocetirizine ((R)-Cetirizine) is a third-generation peripheral H1-receptor antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria .

Cat. No.	Product Name	Target	Research Area

HY-P2244A

YAP-TEAD-IN-1 TFA 2 Publications Verification	YAP	Cancer
YAP-TEAD-IN-1 TFA is a potent and competitive peptide inhibitor of YAP-TEAD interaction (IC₅₀=25 nM). YAP-TEAD-IN-1 TFA is a 17mer peptide and shows a higher the binding affinity to TEAD1 (K_d=15 nM) than YAP (50-171) (K_d= 40 nM) .

HY-P2468

BAD (103-127) (human) BADBH3 103-127 (human); BADBH3 (human)	Bcl-2 Family	Cancer
BAD (103-127) (human), the 25-mer Bad peptide, is derived from the BH3 domain of BAD, can antagonize the function of Bcl-xL. BAD (103-127) (human) is reported to have almost 800-fold higher affinity for Bcl-XL than the 16-mer peptide .

HY-P1135A

M1145 TFA	Neuropeptide Y Receptor	Neurological Disease
M1145 TFA, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a K_i of 6.55 nM. M1145 TFA shows more than 90-fold higher affinity for GAL2 over GAL1 (K_i=587 nM) and a 76-fold higher affinity over GalR3 (K_i=497 nM). M1145 TFA has an additive effect on the signal transduction of galanin .

HY-P3654

α-Conotoxin S IA	nAChR	Neurological Disease
α-Conotoxin SIA is a selective nicotinic acetylcholine receptor (nAChR) antagonist with high affinity for the muscle nAChR. α-Conotoxin SIA preferentially targets the α/δ interface of the muscle nAChR in mouse muscle. In contrast, for Torpedo nAChR, α-Conotoxin SIA has a much higher affinity for the α/γ than for the α/δ interface .

HY-P2244

YAP-TEAD-IN-1	YAP	Cancer
YAP-TEAD-IN-1 is a potent and competitive inhibitor of YAP–TEAD interaction (IC₅₀=25 nM). YAP-TEAD-IN-1 is a 17mer peptide and shows a higher the binding affinity to TEAD1 (K_d=15 nM) than YAP (50-171) (K_d=40 nM) .

HY-P1213A

JKC363 TFA	Melanocortin Receptor	Neurological Disease
JKC363 TFA, a selective melanocortin MC4 receptor antagonist, has a 90-fold higher affinity at the MC4 receptor (IC₅₀=0.5 nM) than at the MC3 receptor (44.9 nM). JKC363 TFA blocks the stimulatory effect of α-MSH on TRH release. Anti-hyperalgesic effect .

HY-P1213

JKC363	Melanocortin Receptor	Neurological Disease
JKC363, a selective melanocortin MC4 receptor antagonist, has a 90-fold higher affinity at the MC4 receptor (IC₅₀=0.5 nM) than at the MC3 receptor (44.9 nM). JKC-363 blocks the stimulatory effect of α-MSH on TRH release. Anti-hyperalgesic effect .

HY-P5421

Caloxin 1B1	Peptides	Others
Caloxin 1B1 is a biological active peptide. (Caloxin 1b1 is obtained by screening for binding to extracellular domain 1 of PMCA4, which inhibited PMCA extracellularly, selectively, and had a higher affinity for PMCA4 than PMCA1. Because caloxin 1b1 had been selected to bind to an extracellular domain of PMCA, it could be added directly to cells and tissues to examine its effects on smooth muscle and endothelium.)

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-14258

Escitalopram 3 Publications Verification (S)-Citalopram; (S)-(+)-Citalopram	Natural Products Source classification Endogenous metabolite	Serotonin Transporter
Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression .

HY-N6785

Okadaic acid 5+ Cited Publications	Structural Classification Animals Ketones, Aldehydes, Acids Marine natural products Source classification Other marine organisms	Phosphatase Apoptosis
Okadaic acid, a marine toxin, is an inhibitor of protein phosphatases (PP). Okadaic acid has a significantly higher affinity for PP2A (IC₅₀=0.1-0.3 nM), and inhibits PP1 (IC₅₀=15-50 nM), PP3 (IC₅₀=3.7-4 nM), PP4 (IC₅₀=0.1 nM), PP5 (IC₅₀=3.5 nM), but does not inhibit PP2C. Okadaic acid increases of phosphorylation of a number of proteins by inhibiting PP, and acts a tumor promoter. Okadaic acid induces tau phosphorylation .

Cat. No.	Product Name	Chemical Structure

HY-14258AS

Escitalopram-d6 oxalate

Escitalopram-d₆ (oxalate) is the deuterium labeled Escitalopram oxalate. Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression[1][2].

HY-18719ES

Endoxifen-d5
Endoxifen-d₅ is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study[1][2].

HY-B0814S

Levocetirizine-d4 dihydrochloride

Levocetirizine-d₄ (dihydrochloride) is the deuterium labeled Levocetirizine. Levocetirizine ((R)-Cetirizine) is a third-generation peripheral H1-receptor antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria[1].

HY-14258AS1

Escitalopram-d4 oxalate

Escitalopram-d₄ (oxalate) is deuterium labeled Escitalopram (oxalate). Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression[1][2].

HY-B0814S1

Levocetirizine-d4

Levocetirizine-d₄ ((R)-Cetirizine-d₄) is the deuterium-labeled Levocetirizine (HY-B0814) . Levocetirizine ((R)-Cetirizine) is a third-generation peripheral H1-receptor antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks